• Thu. May 30th, 2024

From Pfizer to Novavax: Examining the Financial Winners and Losers of the Covid Vaccine


Mar 25, 2024

The Covid-19 pandemic, which began four years ago, has had a devastating impact on the world, claiming the lives of millions of people. One of the key strategies in controlling the spread of the virus was the development of effective vaccines, which have played a crucial role in saving lives.

Despite the success of these vaccines, the financial gains for companies like Pfizer, BioNTech, and Moderna have not been as robust as one might expect. While the revenues generated from the sale of vaccines were substantial, investors have not viewed them as sustainable sources of income.

For example, the sales of the Pfizer/BioNTech vaccine exceeded $80 billion, with millions of doses administered in the U.S. alone. However, Pfizer’s stock price has fallen by 32% over the past five years, indicating that investors are not convinced of its long-term profitability. In contrast, AstraZeneca, which has not included vaccine sales in its financial reports since last April, has seen its share price rise by 64%. Similarly, Merck, whose vaccine efforts were unsuccessful, has seen a 56% increase in its stock price.

Despite the significant sales of vaccines and their role in mitigating the pandemic, investors have not viewed these revenues as indicators of future success for pharmaceutical companies. The dynamic nature of the market and the uncertainty surrounding the long-term demand for vaccines have led to mixed reactions from investors in the pharmaceutical industry.

By editor

Leave a Reply